Skip to main content
main-content

06-11-2021 | ACR 2021 | Conference coverage | Video

The ARIAA trial of abatacept for subclinical arthritis

Jürgen Rech outlines the findings from the ARIAA trial, which demonstrated benefits of abatacept in people at risk for rheumatoid arthritis, and discusses the potential role of treating subclinical inflammation to delay or prevent the onset of clinical disease (7:04).

Read transcript

ACR Convergence 2021 highlights

3–9 November: Keep up with the latest news and interviews from the conference.

Image Credits